Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.

All CIRM Grants

Search Filters »

Disease Focus

Institution

Program Type

Grant Type

Human Stem Cell Use

Cell Line Generation

Collaborative Funder

Award Status

Institution Researcher name Grant Type Grant Title Award Value
University of California, Santa Barbara Dr. Dennis O. Clegg Dr. Shared Labs Grant – Enhancing/Expanding SRLs Shared Resources Laboratory for Stem Cell-Based Modeling in Stem Cell Biology and Engineering $3,999,995
University of California, San Francisco Erik Ullian Foundation – Discovery Stage Research Projects Modeling Retinitis Pigmentosa using patient-derived human iPSC organoids $1,380,543
Children’s Hospital of Los Angeles Dr Biraj Mahato Quest – Discovery Stage Research Projects Chemically engineered photoreceptors for vision restoration in retinal degeneration associated blindness. $1,711,000
Adverum Biotechnologies Inc. Cameron Keast Baker Quest – Discovery Stage Research Projects Development of an Optogenetic Vision Restoration Gene Therapy Using an Engineered Form of Melanopsin $1,150,820
University of California, Los Angeles Dr. Xian-Jie Yang Quest – Discovery Stage Research Projects Developing gene therapy for dominant optic atrophy using human pluripotent stem cell-derived retinal organoid disease models $1,345,691
University of California, San Diego Dr. Jonathan H Lin Quest – Discovery Stage Research Projects Small Molecule Proteostasis Regulators to Treat Photoreceptor Diseases $1,153,937
University of California, San Diego Karl Karl J. Wahlin Inception – Discovery Stage Research Projects An IPSC cell based model of macular degeneration for drug discovery. $232,200
University of Southern California Biju B. Thomas Inception – Discovery Stage Research Projects A Novel Tissue Engineering Technique to Repair Degenerated Retina $215,133
Stanford University Jeffrey L Goldberg Inception – Discovery Stage Research Projects Embryonic Stem Cells for Corneal Endothelial Degeneration $235,836
University of California, San Diego Karl Karl J. Wahlin Inception – Discovery Stage Research Projects Microenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors. $232,200
Ray Therapeutics, INC Paul Bresge Therapeutic Translational Research Projects Optogenetic Therapy for Treatment of Geographic Atrophy $3,998,930
University of California, Los Angeles Anthony J Aldave Therapeutic Translational Research Projects AAV Gene Therapy for Treating Congenital Hereditary Endothelial Dystrophy associated with Biallelic SLC4A11 Mutations $4,338,166
University of California, Los Angeles Dr. Sophie X Deng Therapeutic Translational Research Projects Extracellular Vesicle-Based Therapy for Corneal Scars $5,779,276
Ray Therapeutics, INC Paul Bresge Therapeutic Translational Research Projects Optogenetic therapy for treating retinitis pigmentosa and other inherited retinal diseases $3,999,553
University of Southern California Mark Salman Humayun Therapeutic Translational Research Projects PRPE-SF, polarized hESC-derived RPE Soluble Factors, as a Therapy for Early Stage Dry Age-related Macular Degeneration $3,697,935
Stanford University Dr. Theodore Leng Therapeutic Translational Research Projects NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration $4,235,758
University of California, Los Angeles Steven Schwartz Therapeutic Translational Research Projects Clinical Translation of Autologous Regenerative Cell Therapy for Blindness $5,068,026
University of California, Irvine Dr. Magdalene J Seiler Therapeutic Translational Research Projects Morphological and functional integration of stem cell derived retina organoid sheets into degenerating retina models $4,769,039
University of California, Los Angeles Mark Wisniewski Conference II Los Angeles Bioscience Ecosystem Summit Twenty 24 (LABEST 24) $50,000
Ray Therapeutics, INC Paul Bresge Clinical Trial Stage Projects Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa $7,975,224
Luxa Biotechnology Dr. Jeffrey H Stern Clinical Trial Stage Projects RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration $4,009,675
Regenerative Patch Technologies LLC Jane Stephanie Lebkowski Clinical Trial Stage Projects A Phase 2b, Randomized, Assessor-Masked Clinical Trial to Assess the Safety and Efficacy of the CPCB-RPE1 Implant in Subjects with Geographic Atrophy $12,373,748
Combangio, Inc. R. Kim Brazzell Clinical Trial Stage Projects Phase 2b Clinical Study of KPI-012 Topical Ophthalmic Human Mesenchymal Stem Cell Secretome for the Treatment of Persistent Corneal Epithelial Defect $15,000,000
Immusoft Corporation Dr Robert Hayes Clinical Trial Stage Projects A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 $8,000,000
University of California, Los Angeles Dr. Sophie X Deng Clinical Trial Stage Projects Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency $10,301,486
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Clinical Trial Stage Projects Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa $10,444,063
jCyte, Inc. Henry John Klassen Clinical Trial Stage Projects A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa $5,175,000
jCyte, Inc. Henry John Klassen Clinical Trial Stage Projects Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa $8,295,750
Blue Gen Therapeutics Foundation Aaron Nagiel Late Stage Preclinical Projects Development of a novel intravitreal AAV gene therapy for the rare disease blue cone monochromacy. $4,691,936
University of Southern California Mark Salman Humayun Late Stage Preclinical Projects IND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration $5,993,562
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Late Stage Preclinical Projects Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness $6,000,000
University of California, Los Angeles Dr. Sophie X Deng Late Stage Preclinical Projects Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy $4,244,211
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
University of California, Berkeley John Dueber Tools and Technologies III Engineered Biomaterials for Scalable Manufacturing and High Viability Implantation of hPSC-Derived Cells to Treat Neurodegenerative Disease $1,239,276
University of Southern California Mark Salman Humayun Disease Team Planning Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $3,088
University of Southern California Mark Salman Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
University of California, Irvine Dr. Magdalene J Seiler Early Translational IV Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) $3,998,948
University of California, San Diego Dr. Kang Zhang M.D. Tissue Collection for Disease Modeling Generation of fibroblast cell lines in patients with common blinding eye diseases $1,034,425
Buck Institute for Age Research Deepak A Lamba Basic Biology IV 3D Modeling of Retina using Polymer Scaffolds for Understanding Disease Pathogenesis $1,212,553
University of California, Irvine Dr. Henry John Klassen Disease Team Therapy Development – Research Retinal progenitor cells for treatment of retinitis pigmentosa $17,144,825
University of California, Los Angeles Dr. Sophie X Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $697,507
University of California, Los Angeles Dr. Sophie X Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
University of California, Irvine Dr. Henry John Klassen Early Translational II Human retinal progenitor cells as candidate therapy for retinitis pigmentosa $1,803,768
University of California, Santa Barbara Professor Peter J Coffey Research Leadership Development of Cellular Therapies for Retinal Disease $4,690,963
Calibr Dr. Martin Friedlander Early Translational I Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration $5,806,321
University of California, Los Angeles Dr. Gabriel H. Travis Early Translational I Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
University of Southern California Dr. David R. Hinton SEED Grant Therapeutic potential of Retinal Pigment Epithelial cell lines derived from hES cells for retinal degeneration. $651,607
University of Southern California Mark Salman Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916

How to Apply

Learn More

Explore CIRM-Funded Clinical Trials

Learn More

Managing Your Grant

Learn More

See our Active Awards Portfolio

Learn More